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Previous vaccine efforts with Ebola virus Zaire (EBOV-Z) emphasized the potential protective efficacies of immune
responses to the surface glycoprotein and the nucleoprotein. To determine whether the VP24, VP30, VP35, and VP40 proteins
are also capable of eliciting protective immune responses, these genes were expressed from alphavirus replicons and used
to vaccinate BALB/c and C57BL/6 mice. Although all of the VP proteins were capable of inducing protective immune
responses, no single VP protein protected both strains of mice tested. VP24, VP30, and VP40 induced protective immune
responses in BALB/c mice, whereas C57BL/6 mice survived challenge only after vaccination with VP35. Passive transfer of
immune sera to the VP proteins did not protect unvaccinated mice from lethal disease. The demonstration that the VP
proteins are capable of eliciting protective immune responses to EBOV-Z indicates that they may be important components
of a vaccine designed to protect humans from Ebola hemorrhagic fever.
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iINTRODUCTION
Ebola viruses (EBOVs) are members of the family
Filoviridae and are associated with outbreaks of highly
lethal hemorrhagic fever in humans and nonhuman
primates. Three different EBOV subtypes (Zaire, Su-
dan, and Ivory Coast) have been isolated from human
infections, with the highest case fatality rates (greater
than 80%) being associated with the Zaire subtype
(Johnson et al., 1977, Khan et al., 1999). The natural
reservoir of the EBOV is unknown and no vaccines or
effective therapeutic treatments are currently available
for human use. Because of the severe pathogenicity of
EBOV, live virus vaccines are not generally considered
to be a feasible option for vaccination. Similarly, killed
vaccines have a risk associated both with production
and with incomplete inactivation of the virus. Based on
these concerns, EBOV vaccine efforts have shifted
toward developing vaccines that contain only one or a
few EBOV proteins.
Seven structural proteins and one nonstructural pro-
tein are encoded in the nonsegmented single-stranded
negative-sense RNA genome of EBOV (Sanchez et
al.,1993; Volchkov et al., 1995). The structural proteins
consist of a type I transmembrane glycoprotein (GP), a
nucleoprotein (NP), four virion structural proteins (VP24,
VP30, VP35, and VP40), and an RNA-dependent RNA
polymerase (L). The transmembrane GP, which is ex-
pressed after RNA editing (Volchkov et al., 1995; Sanchez
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384et al., 1996), presumably mediates viral entry into host
cells by receptor binding and membrane fusion and is
the only viral protein known to be on the surface of
virions and infected cells. The nonstructural glycoprotein
sGP, which is encoded by the unedited GP mRNA, is
synthesized in infected cell cultures (Volchkov et al.,
1995; Sanchez et al., 1996) and can be found in the sera
f patients infected with EBOV (Sanchez et al., 1999).
The NP, VP30, VP35, and L proteins associate with the
enomic RNA in a ribonucleoprotein complex (Elliott et
l., 1985). Using an artificial replication system, Mu¨hl-
erger et al. (1999) demonstrated that the NP, VP35, and
proteins are essential for replication and encapsidation
f the EBOV genome. Although VP30 was not essential
or replication, it appeared to be necessary for efficient
ranscription in this system. The NP, VP35, VP30, and L
roteins have also recently been shown to be essential
or the recovery of infectious EBOV-Z from cloned cDNAs
Volchkov et al., 2001). In addition to being an essential
omponent of the replication complex, VP35 was also
ecently implicated as an interferon antagonist (Basler et
l., 2000). VP35 may therefore facilitate viral replication in
nfected cells by blocking the induction of antiviral im-
une responses normally induced by the production of
nterferon.
In contrast, the VP40 and VP24 proteins are mem-
rane-associated and are most likely located on the
nside of the membrane (Elliott et al., 1985). VP40 has
een shown to associate with cell membranes, where it
s believed to be involved in maturation of the virus by
nducing viral assembly at the plasma membrane of
nfected cells (Ruigrok et al., 2000; Dessen et al., 2000).
(
r
E
c
d
C
E
g
s
v
c
s
w
w
i
r
p
s
a
s
t
v
B
385VACCINE POTENTIAL OF EBOLA VIRUS VP PROTEINSThe function of VP24 is not known but it may serve as a
minor matrix protein, facilitating the interaction of VP40
and/or GP with the RNP complex, or function in the
uncoating of the virion during infection (Peters et al.,
1996).
Most of the efforts to develop vaccines to EBOV have
examined the protective capacity of the GP and the NP.
Protection against EBOV-Z has been induced in rodent
models by GP or NP expressed from Venezuelan equine
encephalitis (VEE) virus replicons (Pushko et al., 1997a,
2000; Wilson and Hart, 2001), recombinant vaccinia vi-
ruses (Gilligan et al., 1997), or naked DNA constructs
Vanderzanden et al., 1998; Xu et al., 1998). However,
eplicons expressing the EBOV-Z GP, or a combination of
BOV-Z GP and NP, failed to protect cynomologus ma-
aques from a subcutaneous EBOV-Z challenge with a
ose of 103 plaque-forming units (PFU) (J. Smith and P.
Jahrling, personal communication). Recently, a DNA
prime-adenovirus boost strategy was used to protect
cynomologus macaques from a 6 PFU intraperitoneal (ip)
EBOV-Z challenge (Sullivan et al., 2000), suggesting that
it should be possible to develop a human-use vaccine for
EBOV.
Collectively, studies published to date suggest that
both antibody and cytotoxic T cell (CTL) responses
should be induced to confer optimal immunity to EBOV
in humans. Using passive and adoptive transfer stud-
ies, we demonstrated that monoclonal antibodies to
the GP (Wilson et al., 2000) and CTLs specific for the
NP (Wilson and Hart, 2001) can protect unvaccinated
mice from a lethal challenge of EBOV. If CTLs have an
important role in the ability of humans to survive EBOV
infection, then the optimal vaccine would be one that
provides the most opportunities to induce CTLs. As
only a limited number of CTL epitopes on a given viral
protein are capable of being presented by a particular
class I-MHC molecule, it may be necessary to include
several EBOV proteins in a vaccine that is capable of
inducing CTLs in human populations with diverse
MHC binding motifs.
To date, the ability of the EBOV VP proteins to induce
protection has been examined by expressing the pro-
teins from vaccinia virus and evaluating efficacy in a
guinea pig model (Gilligan et al., 1997; Chepurnov et
al., 1997). There have been no reports of protective
immunity induced by the VP proteins. Because of the
potential importance of these proteins in the develop-
ment of an optimal vaccine for EBOV, we evaluated the
ability of the EBOV-Z VP24, VP30, VP35, and VP40
proteins to elicit protective immunity in two strains of
mice. We selected mice that differ genetically, includ-
ing at the major histocompatibility locus, to evaluate
the efficacy of these proteins against different genetic
backgrounds.
p
tRESULTS
Construction and characterization of replicon vectors
expressing the EBOV VP proteins
To evaluate the ability of the EBOV-Z VP proteins to
serve as protective antigens, we expressed the EBOV-Z
VP24, VP30, VP35, and VP40 proteins from VEE virus
replicon vectors. The advantages of this vaccine vector
include a tropism for antigen-presenting dendritic cells,
high levels of expression of heterologous proteins in the
cytoplasm of infected cells, and the induction of cellular,
mucosal, and humoral immunity to heterologous anti-
gens that are cloned in the place of the structural genes
of the VEE virus (Davis et al., 1996; Pushko et al., 1997b;
aley et al., 1997; MacDonald and Johnston, 2000).
To construct VEE virus replicons expressing the
BOV-Z VP genes, RT-PCR products containing the VP
enes of EBOV-Z (isolate Mayinga) were inserted down-
tream of the 26S promoter in the VEE virus replicon
ector. SDS gel electrophoresis of proteins immunopre-
ipitated from cells transfected with the replicon con-
tructs confirmed that the expressed EBOV-Z proteins
ere of the predicted size (Fig. 1). Lower molecular
eight species were also observed in the lane contain-
ng VP40. We did not determine whether these proteins
epresented proteolytic degradation products or cellular
roteins that coimmunoprecipitated with VP40; however,
imilar findings were observed for VP40 expressed from
recombinant vaccinia virus (Gilligan et al., 1997). DNA
equence analysis showed that the coding sequences of
he VP24, VP35, and VP40 genes cloned in the replicon
ector were identical to those previously described (Gen-
ank Accession Nos. L11365.1 and AF086833). The VP30
FIG. 1. Immunoprecipitation of 35S-labeled proteins expressed in BHK
cells with polyclonal rabbit anti-EBOV serum. BHK cells were trans-
fected with replicon RNAs encoding either EBOV-Z VP24, VP30, VP35,
or VP40. The structural proteins from EBOV-Z (virion) grown in Vero E6
cells are shown. Proteins were resolved under reducing conditions on
an 11% SDS–polyacrylamide gel.rotein expressed from the replicon vector was identical
o that reported by Volchkov et al. (GenBank Accession
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386 WILSON ET AL.No. AF086833) with the exception that it contained 37
amino acids of irrelevant sequence in the place of its
C-terminal proline residue. However, the addition of
these amino acids did not alter the reactivity of the
expressed VP30 protein with anti-EBOV antisera which
recognizes native EBOV-Z VP30 (Fig. 1).
Evaluation of protective antigens in mice
To evaluate the protective efficacy of the EBOV-Z VP
proteins, the replicon constructs expressing the VP pro-
teins from the Mayinga isolate of EBOV-Z were packaged
into virus-like replicon particles (VRPs) and injected into
two strains of mice that genetically differ, including at the
MHC locus. Control mice were injected with VRPs ex-
pressing the N protein of Lassa virus. BALB/c (H-2d) or
57BL/6 (H-2b) mice were vaccinated two or three times
at 1-month intervals with 2 3 106 focus-forming units of
he VRPs and were challenged by ip inoculation of 300
D50 of mouse-adapted EBOV-Z (Bray et al., 1998) 1
month after the final booster injection.
T
Survival of Mice Vaccinated wit
VRP Dosesa S/Tb MDDc
A. BA
EBOV VP24 3 18/20 8 6 1
2 19/20 6
EBOV VP30 3 17/20 7 6 0
2 11/20 7 6 1
EBOV VP35 3 5/19 7 6 1
2 4/20 7 6 2
EBOV VP40 3 14/20 8 6 1
2 17/20 7 6 1
Lassa N 3 0/20 7 6 1
2 0/20 7 6 1
B. C5
EBOV VP24 3 0/20 7 6 0
EBOV VP30 3 2/20 8 6 1
EBOV VP35 3 14/20 8 6 1
EBOV VP40 3 1/20 7 6 1
Lassa N 3 1/20 7 6 1
a Mice were injected two or three times at 1 month intervals with 2 3
he control Lassa N protein.
b S/T, survivors/total challenged with 300 LD50 of mouse-adapted EB
c MDD, mean day of death of mice that died after EBOV challenge.
d Number of mice with detectable antibody (Ab) responses/number t
samples were negative from individual mice tested in one experiment
e GMT, geometric mean titer calculated from endpoint titers of prec
antigen. For EBOV-vaccinated animals, mice without detectable antibo
f GMT, geometric mean titer calculated from the sera of separate gro
ost-EBOV challenge. All mice were viremic when tested, n 5 5 for all
that received two injections of EBOV-Z VP24 VRPs.Vaccination with VRPs encoding the EBOV-Z VP24,
VP30, or VP40 protein protected the majority of theBALB/c mice from lethal EBOV challenge (Table 1A). The
highest levels of protection (90–95%) were observed after
vaccination with VRPs expressing EBOV-Z VP24 (Table
1A). In a similar experiment, two inoculations of VRPs
encoding the EBOV-Z VP24 protein also protected 5/5
BALB/c mice from a 3 3 104 LD50 challenge dose and 5/5
ALB/c mice from a 3 3 106 LD50 challenge dose. Three
injections of VRPs encoding EBOV-Z VP30 induced pro-
tection from lethal disease in 85% of the BALB/c mice
examined. However, when the vaccination schedule was
decreased to two injections, only 55% of the mice immu-
nized with VP30 survived challenge. Vaccination with
VRPs encoding the VP40 protein protected 85 and 70% of
the BALB/c mice after either two or three injections,
respectively. In contrast, the VP35 protein was not effi-
cacious in the BALB/c mouse model, as only 20 and 26%
of the mice were protected from lethal challenge after
either two or three doses, respectively. The mean day of
death of the VP-vaccinated mice that succumbed to the
EBOV challenge was within 1 day of the control Lassa
Encoding EBOV-Z VP Proteins
#Ab Positived
ELISA GMTe
(Log10)
Viremia, GMT f
(Log10 PFU/mL)
ice
19/20 2.4 6 0.2 5.2 6 0.3
18/20 2.4 6 0.2 4.8 6 1.0
20/20 2.6 6 0.3 6.2 6 0.7
18/20 2.3 6 0.3 6.5 6 0.8
17/19 3.6 6 0.5 6.9 6 0.9
16/20 2.9 6 0.6 6.5 6 0.9
20/20 4.3 6 0.4 4.6 6 1.5
20/20 4.1 6 0.4 5.6 6 0.4
0/10 ,2.0 8.0 6 0.3
0/10 ,2.0 8.4 6 0.4
Mice
11/20 2.5 6 0.3 8.6 6 0.2
18/20 2.7 6 0.5 7.7 6 1.3
20/20 3.0 6 0.6 4.5 6 1.0
19/20 3.4 6 0.5 7.8 6 0.5
0/10 ,2.0 8.6 6 0.7
cus-forming units of VRPs encoding individual EBOV-Z VP proteins or
n ELISA at a serum dilution of 1:100. For Lassa N-vaccinated mice, all
0) or pooled from separate experiments.
e sera in ELISA using irradiated, sucrose-purified EBOV-Z virions as
a serum dilution of 1:100 are not included.
mice sacrificed on day 4 (for BALB/c mice) or day 5 (for C57BL/6 mice)
except n 5 4 for Lassa N-vaccinated C57BL/6 mice and BALB/c miceABLE 1
h VRPs
LB/c M
7BL/6
106 fo
OV-Z.
ested i
(n 5 1
halleng
dies at
ups ofN-vaccinated mice (Table 1A). When measured in a
plaque assay, all of the BALB/c mice that were vacci-
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387VACCINE POTENTIAL OF EBOLA VIRUS VP PROTEINSnated with the EBOV-Z VP antigens had measurable
levels of infectious EBOV in the sera 4 days after chal-
lenge (Table 1A). However, vaccination reduced the level
of viremia more than 2 log10 compared to controls.
In contrast to the efficacy observed in the BALB/c
mice, C57BL/6 mice were protected from lethal EBOV
challenge only after vaccination with the EBOV-Z VP35
protein, with 70% of the mice protected after three inoc-
ulations (Table 1B). When the viral titers were measured
5 days after challenge, vaccination with VRPs encoding
the EBOV-Z VP35 protein reduced the viral load by at
least 4 log10 compared to control mice (Table 1B). In
ontrast, viral titers in the sera of C57BL/6 mice vacci-
ated with the EBOV-Z VP24, VP30, or VP40 VRPs were
ithin 1 log of the control mice. Similar to what was
bserved with the BALB/c mice, the mean day of death of
57BL/6 mice that were not protected by VRPs encoding
he EBOV-Z VP proteins was within 1 day of the control
ice injected with the Lassa N VRP (Table 1B).
ntibodies to VP proteins
Most of the mice had detectable EBOV-Z-specific se-
um antibodies after vaccination with VRPs encoding the
BOV-Z VP proteins (Table 1). For the vaccinated groups
hat were protected from EBOV challenge, passive trans-
er studies were performed to determine whether anti-
odies to the VP proteins are capable of conferring
esistance to lethal EBOV disease. Sera were obtained
rom mice previously vaccinated with VRPs expressing
ither one of the EBOV-Z VP proteins, the negative-
ontrol Lassa N or the positive-control EBOV-Z GP. One
illiliter of pooled immune sera was passively adminis-
ered to syngeneic, unvaccinated mice 24 h before chal-
enge with 300 LD50 of mouse-adapted EBOV-Z. When the
ooled donor sera were tested for in vitro inhibition of
BOV-Z plaque formation, a 1:20 dilution of antisera to
he GP or the VP proteins did not inhibit plaque formation
y the mouse-adapted EBOV-Z by 80% compared to con-
rol wells. Despite the absence of in vitro neutralization
ctivity, most of the mice receiving the control immune
era to GP survived lethal challenge (Table 2). In con-
rast, antisera to the EBOV-Z VP24, VP30, VP35, and VP40
roteins, which demonstrated ELISA titers similar to vac-
inated animals prior to EBOV challenge, failed to protect
he recipient mice from EBOV challenge or extend the
ime to death compared to control mice receiving Lassa
immune serum (Table 2).
DISCUSSION
EBOVs are extremely lethal pathogens for which no
accines or effective therapeutic measures are available.
n this study, we examined the ability of the EBOV-Z VP
roteins to serve as protective antigens in a murine
odel of Ebola hemorrhagic fever. We found that high
evels of protection could be induced by vaccination with
t
mny of the four VP proteins of EBOV-Z, but that protection
as dependent on the mouse strain tested.
The observed VP-induced protection in mice differs
rom previous studies (Gilligan et al., 1997; Chepurnov et
l., 1997) in which recombinant vaccinia viruses express-
ng either the EBOV-Z VP24, VP35, or VP40 proteins failed
o protect guinea pigs from lethal challenge with guinea
ig-adapted EBOV-Z. It is not clear if this is due to the
ifferent animal models examined or the different vector
nd vaccination schedules used in the studies. However,
ifferences in protective efficacy were also observed
reviously when VRPs expressing EBOV-Z NP success-
ully protected BALB/c and C57BL/6 mice (Pushko et al.,
000; Wilson and Hart, 2001) but not strain 2 or strain 13
uinea pigs (Pushko et al., 1997a, 2000). Differences in
rotective efficacy of DNA vaccination with EBOV-Z NP
ave also been observed in Hartley guinea pigs depend-
ng on the vaccination schedule examined (Xu et al.,
998). We also observed differences in the ability of the
BOV-Z VP proteins to induce protective responses in
ice with different MHCs. We could not vaccinate with
ny one EBOV-Z VP protein to achieve protection in both
ouse strains, and only one of the four EBOV-Z VP
roteins was efficacious for C57BL/6 mice. As trans-
erred antisera did not confer protection against lethal
hallenge, it is possible that the failure of some mice and
uinea pigs to survive challenge after vaccination with
TABLE 2
Protection from EBOV by Passive Transfer of Immune Sera
Donor seraa S/Tb MDDc ELISA GMTd (Log10)
A. BALB/c Mice
EBOV GP 15/20 8 6 1 4.0 6 0.3
EBOV VP24 0/20 6 6 1 2.6 6 0.0
EBOV VP30 0/20 7 6 1 2.7 6 0.1
EBOV VP40 0/20 6 6 1 4.3 6 0.1
Lassa N 0/20 7 6 1 ,2.0
B. C57BL/6 Mice
EBOV GP 17/20 7 6 2 3.8 6 0.1
EBOV VP35 0/20 7 6 1 2.8 6 0.0
Lassa N 0/20 7 6 1 ,2.0
a Donor sera were obtained 28 days after the third immunization with
3 106 focus-forming units of VRPs encoding the indicated EBOV-Z
protein or the Lassa N protein. One milliliter of pooled donor sera was
administered ip to unvaccinated, syngeneic mice 24 h before chal-
lenge.
b S/T, survivors/total challenged with 300 LD50 of mouse-adapted
BOV-Z.
c MDD, mean day of death of mice that died after EBOV challenge.
d GMT, geometric mean titer calculated from endpoint titers of pooled
donor sera used in passive transfer experiments. ELISAs were per-
formed using irradiated, sucrose-purified EBOV-Z virions as antigen.hese proteins is due to a poor CTL response. The
ouse model used in this study has a very low LD50
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388 WILSON ET AL.(approximately one virion or 0.03 to 0.04 plaque-forming
units) and viremias approaching 9 log10 are observed in
infected mice (Table 1; Bray et al., 1998). We routinely
challenged the mice in this study with 300 LD50 of
mouse-adapted EBOV-Z. It is possible that the higher
challenge dose of guinea pig-adapted EBOV-Z (1 3 103
to 1 3 104 LD50) used in some guinea pig studies (Gilli-
gan et al., 1997, Chepurnov et al., 1997, Pushko et al.,
997a, 2000) may have overwhelmed the induced im-
une responses. However, BALB/c mice vaccinated with
BOV-Z VP24 were protected from lethal disease even
hen the challenge dose was increased up to 1 3 105
PFU (3 3 106 LD50).
We could not demonstrate a role for antibodies in
mediating the VP-induced protection, which was not un-
expected, as the VP proteins are not found on the surface
of virions or infected cells and are presumed to be
inaccessible to the protective effects of antibodies. The
titers of the antibodies induced by vaccination with the
EBOV-Z VP proteins were similar in both strains of mice
tested (Table 1). Therefore, the inability of the VP proteins
to protect both strains of mice did not appear to be due
to an inability of the humoral immune system to respond
to the antigens.
The detection of viremia after challenge indicates that
vaccination with the EBOV-Z VP proteins did not induce
sterile immunity. This finding was not surprising, given
the lack of protection observed in the antibody transfer
studies and the fact that other immune mechanisms,
such as CTLs, would be involved only after viral infection
had occurred. However, vaccination with the EBOV-Z VP
proteins significantly reduced viral replication in the pro-
tected groups and enabled the mice to survive the EBOV
challenge. It is likely that a strong CTL response to the
VP proteins was capable of controlling viral replication
early in infection. It remains to be determined if the ability
of the VP proteins to protect against lethal EBOV chal-
lenge is due to the ability to mount an effective CTL
response, but our observation that the EBOV-Z VP pro-
teins differed in their ability to induce protective immune
responses in MHC-disparate mice is compatible with
this suggestion.
The inability of some animals to mount protective re-
sponses to individual EBOV proteins highlights the need
to thoroughly examine the immune mechanisms mediat-
ing protection as well as the ability of vaccine vectors to
effectively induce those responses. It also indicates that
an eventual EBOV vaccine will probably have to include
several EBOV proteins to induce protection in recipients
with diverse MHC proteins. Our finding that protective
immunity to a lethal EBOV challenge can be induced in
mice by vaccination with the EBOV-Z VP24, VP30, VP35,
and VP40 proteins indicates that these proteins warrant
further consideration as components of an eventual vac-
cine candidate for EBOV.
t
pMATERIALS AND METHODS
Cells lines and viruses
Baby hamster kidney (BHK, ATCC CCL 10), Vero 76
(ATCC CRL 1587), and Vero E6 (ATCC CRL 1586) cell lines
were maintained in minimal essential medium (MEM)
with Earle’s salts, 10% fetal bovine serum, and 50 mg/ml
f gentamicin sulfate.
The mouse-adapted EBOV-Z was previously obtained
y serial passage of the EBOV-Z (isolate Mayinga) in
ice (Bray et al., 1998). Frozen aliquots of a double-
laque-purified ninth-mouse-passage isolate were used
n all mouse challenge experiments and neutralization
ssays. This virus is uniformly lethal for immunocompe-
ent adult mice by ip inoculation, with an LD50 of approx-
mately one virion (0.03–0.04 Vero E6 plaque-forming
nits) (Bray et al., 1998). The 1976 and 1995 isolates of
BOV-Z were provided by P. B. Jahrling.
loning of EBOV genes and construction of replicon
NA
A plasmid encoding the VEE replicon vector contain-
ng a unique ClaI site downstream from the 26S promoter
as described previously (Davis et al., 1996). The
BOV-Z GP and the Lassa N genes were previously
loned into the VEE replicon vector as described
Pushko et al., 1997a,b).
The EBOV-Z VP genes used in this study were cloned
y RT-PCR of RNA from EBOV-Z (strain Mayinga)-infected
ero E6 cells. First-strand synthesis was primed with
ligo(dT) (Life Technologies). Second-strand synthesis
nd subsequent amplification of viral cDNAs were per-
ormed with the gene-specific primers listed below. The
rimer sequences were derived from a previously pub-
ished sequence for EBOV-Z (Sanchez et al., 1993) and
ere designed to contain a ClaI restriction site for clon-
ng the amplified VP genes into the ClaI site of the
eplicon vector. The VP24 forward primer was 59-GG-
ATCGATCTCCAGACACCAAGCAAGACC-39, the VP24
everse primer was 59-GGGATCGATGAGTCAGCATATAT-
AGTTAGCTC-39, the VP30 forward primer was 59-
CCATCGATCAGATCTGCGAACCGGTAGAG-39, the VP30
everse primer was 59-CCCATCGATGTACCCTCATCA-
ACCATGAGC-39, the VP35 forward primer was 59-GG-
ATCGATAGAAAAGCTGGTCTAACAAGATGA-39, the VP35
everse primer was 59-CCCATCGATCTCACAAGTGTATCAT-
AATGTAACGT-39, the VP40 forward primer was
9-CCCATCGATCCTACCTCGGCTGAGAGAGTG-39, and
he VP40 reverse primer was 59-CCCATCGATATGTTAT-
CACTATCCCTGAGAAG-39.
PCR products containing individual EBOV-Z VP genes
ere digested with ClaI and cloned into the ClaI site of
he VEE replicon vector downstream from the VEE 26S
romoter.
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389VACCINE POTENTIAL OF EBOLA VIRUS VP PROTEINSProduction of recombinant VEE virus replicons
Replicon RNAs were packaged into particles as de-
scribed (Pushko et al., 1997b). Briefly, capped replicon
RNAs were produced in vitro by T7 runoff transcription of
NotI-digested plasmid templates using the RiboMAX T7
RNA polymerase kit (Promega). BHK cells were cotrans-
fected with the replicon RNAs and two RNAs expressing
the VEE virus structural proteins. The cell culture super-
natants were harvested approximately 30 h after trans-
fection and the replicon particles were concentrated and
partially purified by centrifugation through a 20% sucrose
cushion. Packaged VRPs were suspended in phosphate-
buffered saline (PBS) and titers were determined as
immunofluorescent foci after infection of Vero cells as
described (Pushko et al., 1997b) using either EBOV-im-
mune rabbit serum or mouse monoclonal antibodies to
VP24 (Z-AC01-BG11-01), VP35 (M-HC01-AF11), or VP40
(M-HD06-AD10).
Metabolic labeling and radioimmunoprecipitation of
EBOV proteins
Vero E6 cells (75 cm2 flasks) were infected with the
1995 strain of EBOV-Z at a multiplicity of infection of 1–3
PFU/cell. After 24 h of infection, the growth medium was
removed and cells were starved for 30 min in medium
lacking methionine and cysteine. To label viral proteins,
cells were incubated for 24 h in MEM containing 2%
heat-inactivated fetal bovine serum, 0.1 mCi/ml 35S-la-
eled methionine, and 0.1 mCi/ml 35S-labeled cysteine.
The medium was harvested and centrifuged to remove
cell debris (15 min at 1500 g). Labeled EBOV-Z virions
ere pelleted through a 20% sucrose cushion (3 h at
6,000 rpm in a SW41 rotor) and suspended in Zwitter-
ent lysis buffer (10 mM Tris–HCl, pH 8.0, 0.5 M NaCl, 1
M EDTA, 4% Zwittergent 3-14, and protease inhibitors).
To label proteins expressed by VReps, BHK cells were
lectroporated with VRep RNAs expressing each of the
BOV-Z VP proteins. After 16 h of incubation, cells were
tarved for 30 min in medium lacking methionine and cys-
eine and then incubated for 4 h in MEM medium contain-
ing 0.1 mCi/ml 35S-labeled methionine and cysteine. Cell
monolayers were lysed in Zwittergent lysis buffer and the
EBOV-Z VP proteins were analyzed by immunoprecipitation
as described (Hevey et al., 1997) using EBOV-immune rab-
bit serum. Immunoprecipitated proteins were resolved by
electrophoresis on an 11% SDS–polyacrylamide gel and
were visualized by autoradiography.
Serological assays
Enzyme-linked immunosorbent assays (ELISAs) were
performed essentially as described (Hevey et al., 1997) on
plates coated with irradiated, sucrose-purified EBOV-Z 1995
virions. Absorbance values 0.2 above control samples were
considered positive. Endpoint titers were calculated using afour-parameter curve fit (SOFTmax software, Molecular De-
vices Corp.) of background-subtracted mean OD vs dilution,
followed by extrapolation of the dilution at which the OD
was 0.20. Mice that did not have detectable antibodies to
EBOV are noted but were not included in the geometric
mean titer calculations.
Plaque assays were performed as described (Moe et
al., 1981) with confluent Vero E6 cells. To evaluate the
presence of EBOV-neutralizing antibodies, serial dilu-
tions of mouse sera were mixed with 100 PFU of mouse-
adapted EBOV-Z at 37°C for 1 h and used to infect
confluent Vero E6 cells. None of the samples reduced
the number of plaques by 80% compared to control wells.
Vaccination and challenge of mice
Specific pathogen-free 6- to 8-week-old female
BALB/c or C57BL/6 mice (NCI, Frederick, MD) were
housed in cages equipped with microisolators and pro-
vided food and water ad libitum. Mice were acclimated
for 1 week before vaccination. Research was conducted
in compliance with the Animal Welfare Act and other
federal statutes and regulations relating to animals and
experiments involving animals and adheres to principles
stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 1996. The facility
where this research was conducted is fully accredited by
the Association for Assessment and Accreditation of
Laboratory Animal Care International. Animal experi-
ments were performed a minimum of two times.
Groups of 10 BALB/c or C57BL/6 mice per experiment
were subcutaneously injected at the base of the neck
with 2 3 106 focus-forming units of VRPs encoding the
BOV-Z genes, or with a control replicon encoding the
assa N gene. Booster immunizations were adminis-
ered at 1-month intervals. Survival data are recorded as
he combined results of two separate experiments. Anes-
hetized mice were bled from the retro-orbital sinus 1
eek before challenge to examine antibody titers to the
iral proteins. One month after the final booster injection,
ice were transferred to a BSL-4 containment area and
hallenged by ip inoculation of 300 LD50 (10 PFU) of
ouse-adapted EBOV-Z. The mice were observed daily
or 28 days, which is approximately four times longer
han the mean day of death of control mice, and morbid-
ty and mortality were recorded. Surviving mice were
ack-challenged with 300 LD50 of mouse-adapted
EBOV-Z and monitored for an additional 28 days. All mice
that survived the initial challenge virus also survived the
subsequent back-challenge.
To determine serum viral titers after challenge, four or
five mice from vaccinated and control groups were anes-
thetized and exsanguinated on day 4 (BALB/c mice) or
day 5 (C57BL/6 mice) after challenge. The viral titers in
individual sera were determined by plaque assay. For
passive transfer studies, donor sera were obtained from
t
n
t
C
D
D
E
390 WILSON ET AL.anesthetized mice 28 days after the third inoculation with
VRPs. One milliliter of pooled donor sera was adminis-
tered ip to naive, syngeneic mice 24 h before ip chal-
lenge with 300 LD50 of mouse-adapted EBOV-Z. Anesthe-
ized recipient mice were bled from the retro-orbital si-
us 5 h prior to challenge to determine serum antibody
iters to the EBOV-Z proteins.
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